Research Article
Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
Table 1
Patient characteristics.
| Cohort characteristics | Number | % |
| Age distribution | | | 20–30 | 5 | 3% | 31–40 | 6 | 4% | 41–50 | 15 | 9% | 51–60 | 34 | 20% | 61–70 | 40 | 24% | 71–80 | 38 | 23% | 81–90 | 24 | 14% | >90 | 5 | 3% | Mean age | 65.2 | | Gender | | | Male | 86 | 51.50% | Female | 81 | 48.50% | Distribution by malignancy | | | Breast | 15 | 9% | GI | 19 | 11% | Gyn | 10 | 6% | Colorectal | 14 | 8% | Lung | 23 | 14% | Hematologic | 41 | 25% | Prostate | 13 | 8% | Renal cell | 5 | 3% | Skin | 3 | 2% | Urothelial | 8 | 5% | Head/neck | 6 | 4% | Other | 10 | 6% | Type of anticoagulation | | | Coumadin | 1 | 1% | Dalteparin | 152 | 91% | Enoxaparin | 5 | 3% | Fondaparinux | 7 | 4% | None | 2 | 1% |
|
|